Key Highlights

  • Baird Medical (NASDAQ:BDMD) was down 20.94% to USD 0.1091, despite a China distribution agreement.
  • PAVmed (NASDAQ:PAVM) was up 9.95% to USD 2.10, with no explaining announcement identified.
  • Innovative Eyewear (NASDAQ:LUCY) was down 9.75% to USD 0.75, with no catalyst identified.
  • Rockwell Medical (NASDAQ:RMTI) was up 11.04% at USD 7.67, after a Vantive deal.
  • TriSalus (NASDAQ:TLSI) was down 15.70% to USD 3.06, with no announcement identified.
  • Bioventus (NASDAQ:BVS) was down 19.47% to USD 10.59, after third quarter results.

Baird Medical (NASDAQ:BDMD) (down USD 0.0289, 20.94%): Weaker Despite a Distribution Deal

Baird Medical Investment Holdings (NASDAQ:BDMD) was down 20.94% to USD 0.1091 in pre-market trading on November 3, 2026. On November 2, 2026, it announced an exclusive agreement with a China Resources Pharmaceutical Group Subsidiary covering 19 key markets in China, with an initial order of about RMB 6 million, roughly USD 900,000.

No announcement explaining the decline itself was identified. As a penny stock, thin Liquidity and dilution risk can amplify swings.

PAVmed (NASDAQ:PAVM) (up USD 0.1900, 9.95%): Ahead of the November 13 Call

PAVmed (NASDAQ:PAVM) was up 9.95% to USD 2.10 in pre-market trading on November 3, 2026. No announcement explaining the jump was identified. Its October 30, 2026 release only set a third quarter Business update call for November 13, 2026.

Cash was USD 3.8 million at June 30, 2026, against six-month operating expenses of USD 15.1 million, so the company depends on raising funding. Calculated from those figures, cash covers roughly one quarter of spending at the first-half pace.

Innovative Eyewear (NASDAQ:LUCY) (down USD 0.0810, 9.75%): Lower After a Record Sales Update

Innovative Eyewear (NASDAQ:LUCY) was down 9.75% to USD 0.75 in pre-market trading on November 3, 2026. No announcement dated October 30 to November 3, 2026 was identified as a catalyst.

Preliminary third quarter net sales were about USD 1.04 million, up about 55%, though the figures are unaudited and could change. The release listed the ability to obtain additional financing and continue as a Going Concern among its risk factors. As a penny stock, it carries Volatility and dilution risk.

Rockwell Medical (NASDAQ:RMTI) (up USD 0.7626, 11.04%): A Dialysis Acquisition

Rockwell Medical (NASDAQ:RMTI) was up 11.04% at USD 7.67 in pre-market trading on November 3, 2026. It signed a definitive agreement to acquire Vantive's hemodialysis concentrates, monitors and water treatment systems, excluding dialyzers.

The deal is expected to close in mid-2027, subject to regulatory approvals. The price was not disclosed, and cash and investments were USD 24.8 million at June 30, 2026, so any Equity issuance could dilute holders. Third quarter results are due November 12, 2026.

TriSalus (NASDAQ:TLSI) (down USD 0.5699, 15.70%): A Slide With No Fresh Headline

TriSalus Life Sciences (NASDAQ:TLSI) was down 15.70% to USD 3.06 in pre-market trading on November 3, 2026. No company announcement dated November 2 or 3, 2026 was identified, and no trigger can be confirmed.

Second quarter Revenue was USD 11.4 million, up 1.7%, while full-year guidance of USD 54 million to USD 57 million was maintained, so the second half carries the weight. Cash was USD 46.3 million against long-term Debt of USD 33.1 million, and the company flagged Credit Facility covenant risk.

Bioventus (NASDAQ:BVS) (down USD 2.56, 19.47%): Lower After Third Quarter Results

Bioventus (NASDAQ:BVS) was down 19.47% to USD 10.59 in pre-market trading on November 3, 2026, following its November 2, 2026 report. Net sales were USD 142.4 million, up 2.7%, and adjusted EBITDA rose to USD 28.4 million.

The company continues to review strategic alternatives, which may or may not lead to a transaction. Restorative Therapies sales fell 3.4%, and U.S. sales grew only 1.0%. Cash was USD 30.7 million at September 26, 2026.

Where Things Stand

Only Baird Medical, Rockwell Medical and Bioventus had company news tied to the session, and the largest declines came from Baird Medical and Bioventus. PAVmed, Innovative Eyewear and TriSalus moved without an identified announcement. Items to watch include the PAVmed call on November 13, Rockwell Medical results on November 12, mid-November reports from Innovative Eyewear and any strategic review update from Bioventus.